569251-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 7.5 cm × 4.6 mm, HPLC Column

• Synonym(s): Discovery RP18 HPLC Column
• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Properties

• product name: Discovery^® HS C18 HPLC Column, 3 μm particle size, L × I.D. 7.5 cm × 4.6 mm
• material: stainless steel column
• Quality Level: 100
• Agency: suitable for USP L1
• product line: Discovery^®
• feature: endcapped
• manufacturer/tradename: Discovery^®
• packaging: 1 ea of
• extent of labeling: 20% Carbon loading
• parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• technique(s): HPLC: suitable; LC/MS: suitable
• L × I.D.: 7.5 cm × 4.6 mm
• surface area: 300 m²/g
• surface coverage: 3.2 μmol/m²
• impurities: <10 ppm metals
• matrix: silica gel, high purity, spherical particle platform; fully porous particle
• matrix active group: C18 (octadecyl) phase
• particle size: 3 μm
• pore size: 120 Å
• operating pH range: 2-8
• application(s): food and beverages
• separation technique: reversed phase

Description

General description

Discovery^® HS C18 HPLC column (L × I.D. 7.5 cm × 4.6 mm) is generally found to be stable under acidic and basic conditions.

Application

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research demonstrates the use of the Discovery^® HS C18 HPLC Column in developing a robust HPLC method for analyzing molnupiravir, showcasing its importance in current pandemic-related pharmaceutical research (Recber et al., 2022).


• A new RP-HPLC method as an auxiliary tool for optimization of sample preparation procedures for tracing of PPCPs of different hydrophilicities.: Highlights the adaptability of the Discovery^® HS C18 HPLC Column in environmental monitoring, specifically for pharmaceutical and personal care products, enhancing analytical methods for environmental safety (Portillo-Castillo et al., 2021).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This study uses the Discovery^® HS C18 HPLC Column to assess terizidone levels in patient plasma, providing critical insights into the treatment of drug-resistant tuberculosis (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: Depicts the utility of the Discovery^® HS C18 HPLC Column in optimizing liquid chromatography methods for the potent chemotherapeutic agent doxorubicin, underscoring its role in therapeutic drug monitoring (Maliszewska et al., 2018).


• Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: Showcases the Discovery^® HS C18 HPLC Column′s application in studying the permeability and transport of efavirenz across the placenta, providing valuable pharmacological insights (Zelena et al., 2017).

Features and Benefits

• Stable, low bleed for LC-MS applications
• Scalable from analytical to preparatory
• Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
• Higher hydrophobicity for better resolution of difficult analytes

   

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class Code: 13 - Non Combustible Solids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable